BJP women's wing leader Jamila Khan shot dead in Bhopal

Mysuru, Jun 18: The Karnataka government's proposal announced on Thursday to hold online classes for students amid concerns over COVID-19 has not gone down well with thousands of tribal students residing in villages across the state.

A team from Karnataka State Commission for Protection of Child Rights (KSCPCR) visited a few tribal hamlets in Mysuru and Kodagu recently and found that the students, unlike their urban counterparts, lack accessibility to not just smartphones and computers, but basic necessities like power supply.

''When such is the situation in the tribal hamlets, how can you expect students to catch up on their studies if classes are held online?'' wondered M L Parashurama Member, KSCPCR, who toured villages like Thithimathi, Beematagere, Devamachchi and Gaddadi in Kodagu's Virajpet taluk, besides Bavali, Balyadi, Machchuru, and Anemone in Mysuru's HD Kote taluk along with Chairperson Antony Sebastian.

Bengaluru, June 22: BJP leader and Madikeri MLA Appachu Ranjan has urged the Karnataka Chief Minister B S Yediyurappa and Home Minister Basavaraj Bommai to drop cases against the saffron activists who had involved in attacks against cattle traders and transporters across the state.

In a letter addressed to the CM and the Home Minister, the MLA expressed his concern against the illegal transportation and slaughtering of cattle. Cow is considered to be holy in Hinduism. Butchering of cattle has been hurting the religious sentiments of people, he stated.

Ranjan stated that cases had been registered against 'Gau Rakshaks' or cow vigilantes who had fought against the illegal transportation of cattle.

“Filing cases against the protectors of cattle is condemnable. If the cases are not dropped, then there will be none to question the illegal cattle transporters,” he said adding that cases registered against various police stations against cow vigilantes must be dropped.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.